Saad Z. Usmani, MD: In My Experience Question 5
COVID-19 and Cancer CareFor community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?
Recorded April 24, 2020.
For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?
Recorded April 24, 2020.
Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic?
Recorded April 24, 2020.
For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?
Recorded April 21, 2020.
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24, 2020.
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
Jacek Jassem, MD, PhD, of the Medical University of Gdansk, and an international editor on The ASCO Post Editorial Board, talks about the situation in Poland, how his institution is coping, and the adjustments the staff has made to deliver quality cancer care. Filmed April 17, 2020.